AI assistant
Passage BIO, Inc. — Director's Dealing 2024
Feb 14, 2024
34849_dirs_2024-02-13_cf5abe5e-5a5e-421f-be0a-3d3e533eebd7.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Passage BIO, Inc. (PASG)
CIK: 0001787297
Period of Report: 2024-02-10
Reporting Person: Borthwick Kathleen (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-02-10 | Common Stock | M | 4000 | — | Acquired | 29936 | Direct |
| 2024-02-13 | Common Stock | S | 1470 | $.97 | Disposed | 28466 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-02-10 | Restricted Stock Unit | $ | M | 4000 | Disposed | Common Stock (4000) | Direct |
Footnotes
F1: Restricted stock units ("RSUs") convert into common stock on a one-for-one basis.
F2: The sale reported on this Form 4 represents an Issuer mandated sale by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs; it does not represent a discretionary trade by the Reporting Person. Pursuant to the Issuer's equity incentive plan, an award recipient's tax withholding obligations must be funded by a "sell to cover" transaction.
F3: 1/3 of the RSUs will vest on February 10, 2024 and 2/3 of the RSUs will vest on February 10, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date.